Study Overview: This study looks at a new medicine, BFB759, for people with hidradenitis suppurativa, a skin condition causing painful lumps. The study lasts about 36 to 40 weeks. We want to see if BFB759 is better and safer than a placebo, a pill with no active medicine.
- Participation Length: You'll be involved for 36 to 40 weeks.
- Visits: Regular visits are required to check progress.
- Eligibility: Must be 18-75 years old with moderate to severe disease.
Eligibility: You can join if you're an adult (18-75 years) who has had hidradenitis suppurativa for at least a year and if current treatments aren't helping. You must agree to study rules, attend visits, and avoid certain medicines.
Exclusions: You cannot participate if you have certain infections or immune conditions, have recently used interfering medications, or are pregnant or breastfeeding.
How understandable was the trial content above?
Hard to understand
Easy to understand